Public Company Healthcare

Zydus Lifesciences

Ahmedabad, Gujarat, India

The Zydus Group is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Focus Areas
Pharmaceuticals, Biologics, Biosimilars
Website
zyduslife.com

Tracked deals

3

3 tracked deals across 2025-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Zydus Lifesciences Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Zydus Lifesciences. 1 2025 ~3 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Zydus Worldwide DMCC to Acquire Assertio Holdings in All-Cash $166.4 Million Tender Offer
    May 13, 2026
    Buyer
    Zydus Worldwide DMCC, Zydus Lifesciences Limited, Zara Merger Sub Inc.
    Target
    Assertio Holdings, Inc.
    Industry
    Biotechnology
    Location
    Illinois, United States
    Type
    Buyout

    Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, has entered into a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. for $23.50 per share in cash, valuing the deal at approximately $166.4 million. The transaction is structured as a tender offer followed by a second-step merger at the same price and is expected to close in the second quarter of 2026 (2026–27 financial year in some reports), subject to customary conditions.

  • Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC
    January 16, 2026
    Buyer
    Zydus Lifesciences Limited, Zylidac Bio LLC
    Target
    Agenus Inc.
    Seller
    Agenus Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.

  • Zydus Lifesciences Acquires 85.6% of Amplitude Surgical and Launches Mandatory Tender Offer
    March 11, 2025
    Buyer
    Zydus Lifesciences Limited
    Target
    Amplitude Surgical
    Seller
    PAI Partners, Amplitude Surgical management, Two minority shareholders (names not specified)
    Industry
    Medical Devices
    Location
    France
    Type
    Buyout

    Zydus Lifesciences Limited entered into exclusive negotiations to buy a controlling 85.6% stake in Amplitude Surgical, valuing the block at €256.8 million (€6.25 per share), from PAI Partners and certain minority shareholders. After regulatory conditions were fulfilled, the 85.6% stake was completed, and Zydus will file (and then conduct) a simplified mandatory tender offer for the remaining shares at the same €6.25 price, followed by a squeeze-out to delist.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Zydus Lifesciences. Medical Devices Buyers & Acquisitions 1 tracked deal by Zydus Lifesciences. Acquisitions in Illinois 1 tracked deal by Zydus Lifesciences. Acquisitions in Massachusetts 1 tracked deal by Zydus Lifesciences.

Selling a company? Get in front of buyers like Zydus Lifesciences

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →